These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33113546)

  • 21. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
    Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
    Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Fluorescein Angiography Findings in Stage 3 Retinopathy of Prematurity in Zone II Treated With or Without Anti-VEGF.
    Vural A; Demirayak B; Ozbas M; Onur IU; Celik G
    Eur J Ophthalmol; 2022 Nov; 32(6):3281-3288. PubMed ID: 35191353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of optical coherence tomography biomarkers to differentiate favourable and unfavourable responders to intravitreal anti-vascular endothelial growth factor treatment in retinopathy of prematurity.
    Belenje A; Reddy RU; Parmeswarappa DC; Padhi TR; Subbarao B; Jalali S
    Eye (Lond); 2024 Apr; 38(6):1097-1103. PubMed ID: 37968517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity.
    Theophanous C; Schechet S; Rodriguez SH; Blair M
    Ophthalmic Surg Lasers Imaging Retina; 2018 Nov; 49(11):893-896. PubMed ID: 30457649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
    Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
    Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
    Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312 mg Bevacizumab].
    Andrassi-Darida M; Mais C; Stieger K; Lorenz B
    Klin Monbl Augenheilkd; 2020 Dec; 237(12):1468-1476. PubMed ID: 31770787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
    Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
    J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
    Akdogan M; Cevik SG; Sahin O
    Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings.
    Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Garcia Gonzalez JM; Snyder L; Blair M; Rohr A; Shapiro M; Greenwald M
    Retina; 2018 Apr; 38(4):764-772. PubMed ID: 28267112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity.
    Rodriguez SH; Schechet SA; Shapiro MJ; Blair MP
    J AAPOS; 2020 Jun; 24(3):149.e1-149.e5. PubMed ID: 32461148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
    Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
    Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiographic findings in cases with a history of severe retinopathy of prematurity treated with anti-VEGFs: Follow-up to age 6 years.
    Celiker H; Sahin O
    Int Ophthalmol; 2022 Apr; 42(4):1317-1337. PubMed ID: 34729633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early angiographic signs of retinopathy of prematurity requiring treatment.
    Lepore D; Ji MH; Ying GS; Orazi L; Pagliara MM; Quinn GE;
    Eye (Lond); 2021 Nov; 35(11):3094-3101. PubMed ID: 33469135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.